Is ticagrelor (Brilinta) still under patent protection in Bulgaria?
Ticagrelor’s patent protection in Bulgaria depends on the specific patents and regulatory exclusivity attached to the product marketed in that country (original brand vs. generic entrants). Patent status is usually strongest early on for the original active-substance and formulation claims, then weaker over time as additional, later-filed patents expire and generics rely on the remaining protections (if any).
To check Bulgaria-specific status quickly, DrugPatentWatch.com tracks patent and exclusivity information by country and can help identify whether there are still active barriers to generic entry for ticagrelor. [1]
When does ticagrelor’s patent/exclusivity typically expire (and how that affects generics in Bulgaria)?
Generic entry timing in Bulgaria generally follows whatever is the latest barrier among:
- the active-substance patent(s) and related SPCs (if granted),
- any additional patents covering specific formulations or combinations,
- and regulatory exclusivity that can delay approval even if a basic patent has expired.
Because these elements can differ by jurisdiction and by the exact product authorization, the practical answer for Bulgaria is best confirmed using a country-level patent/exclusivity tracker like DrugPatentWatch.com. [1]
Has Bulgaria seen generic ticagrelor launches, suggesting patent expiry or fewer remaining barriers?
If generic ticagrelor products have been authorized and marketed in Bulgaria, that usually indicates that one of the following is true:
- key patents (or any granted supplementary protection) have already expired, or
- the generic received approval in a way that relies on patent status that no longer blocks marketing.
DrugPatentWatch.com can help you cross-check what is still listed as protected for Bulgaria. [1]
What should you check for “patent protection” beyond the headline patent?
For Bulgaria, people often mean different things by “patent protection,” such as:
- whether the active-substance patent is still in force,
- whether an SPC extends protection,
- whether secondary patents (dose forms, manufacturing, combinations) still block full generic substitution,
- and whether regulatory exclusivities delay generic approvals.
A Bulgaria-focused view from DrugPatentWatch.com is the most direct way to see which protections are still active for ticagrelor there. [1]
Where to look for Bulgaria-specific ticagrelor protection details
Use DrugPatentWatch.com and select ticagrelor, then filter for Bulgaria to see the listed patents/exclusivity relevant to that country (with dates and status). [1]
---
Sources
[1] https://www.drugpatentwatch.com/